HA
BMY.RT

Havens Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Havens Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-122,301
Closed -$84K – 66
2020
Q4 		$84K Sell
122,301
-349,699
-74% -$745K 0.08% 39
2020
Q3 		$1.06M Buy
472,000
+132,000
+39% +$377K 0.98% 21
2020
Q2 		$1.22M Buy
340,000
+155,000
+84% +$559K 1.82% 14
2020
Q1 		$703K Buy
185,000
+19,375
+12% +$63.8K 0.69% 24
2019
Q4 		$499K Buy
+165,625
New +$431K 0.44% 28

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Havens Advisors's BMY.RT Position: Q1 2021 in Review

Havens Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 122,301 shares — an estimated $84K sold.

Havens Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.22M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Havens Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Havens Advisors sold 122,301 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $84K.
  • Havens Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Havens Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.22M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Havens Advisors's 13F filing for Q1 2021, filed 14 Apr 2021.